logo

Sesen Bio Inc (SESN)



Trade SESN now with
  Date
  Headline
2/16/2021 7:20:16 AM Sesen Bio Announces FDA Acceptance And Priority Review Of Its BLA For Vicineum
1/13/2021 8:10:23 AM Sesen Bio And Qilu : IND Application For Vicineum Accepted For Review In China
12/21/2020 8:08:52 AM Sesen Bio Announces Submission Of Completed BLA To FDA For Vicineum
12/1/2020 8:08:51 AM Sesen Bio Partners With Hikma Pharma For Commercialization Of Vicineum In Middle East And North Africa
10/26/2020 8:20:11 AM Sesen Bio Says Completes Successful Pre-submission Meeting With EMA For Vicineum1 For BCG-unresponsive NMIBC In Europe
8/10/2020 7:49:16 AM Sesen Bio Q2 Net Loss $26.3 Mln Or $0.24/Shr Vs Net Loss Of $54.3 Mln Or $0.67/Shr Last Year
7/31/2020 7:38:12 AM Sesen Bio Announces Agreement With Qilu For Development And Commercialization Of Vicineum In China
5/11/2020 7:13:48 AM Sesen Bio Q1 Net Income $41.6 Mln Or $0.31/Shr Vs Loss Of $6.5 Mln Or $0.08/Shr Last Year
3/16/2020 7:15:21 AM Sesen Bio Q4 Net Loss Widens To $33.6 Mln From $6.8 Mln Last Year
12/9/2019 7:32:51 AM Sesen Bio Initiates Rolling Submission Of BLA For Vicinium To FDA
11/12/2019 7:14:33 AM Sesen Bio Q3 Net Loss $13.1 Mln Or $0.13/Shr Vs Loss $14.0 Mln Or $0.18/Shr Last Year
6/19/2019 8:17:31 AM Sesen Bio Reports Pricing Of Public Offering Of 20.4 Mln Shares Of Common Stock And Warrants